CNSX:CURA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Curaleaf Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CURA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: CURA's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

6.7%

CURA

9.5%

CA Pharmaceuticals

0.2%

CA Market


1 Year Return

114.0%

CURA

52.2%

CA Pharmaceuticals

2.0%

CA Market

Return vs Industry: CURA exceeded the Canadian Pharmaceuticals industry which returned 47.4% over the past year.

Return vs Market: CURA exceeded the Canadian Market which returned 1.5% over the past year.


Shareholder returns

CURAIndustryMarket
7 Day6.7%9.5%0.2%
30 Day18.5%30.3%3.8%
90 Day48.5%73.1%13.4%
1 Year114.0%114.0%52.2%52.2%5.7%2.0%
3 Yearn/a-52.6%-53.4%13.5%2.7%
5 Yearn/a427.0%423.3%67.8%42.1%

Long-Term Price Volatility Vs. Market

How volatile is Curaleaf Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Curaleaf Holdings undervalued compared to its fair value and its price relative to the market?

7.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CURA (CA$19.2) is trading above our estimate of fair value (CA$14.07)

Significantly Below Fair Value: CURA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CURA is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.

PE vs Market: CURA is unprofitable, so we can't compare its PE Ratio to the Canadian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CURA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CURA is overvalued based on its PB Ratio (7.2x) compared to the CA Pharmaceuticals industry average (2.7x).


Next Steps

Future Growth

How is Curaleaf Holdings forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

48.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CURA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: CURA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CURA's is expected to become profitable in the next 3 years.

Revenue vs Market: CURA's revenue (28.4% per year) is forecast to grow faster than the Canadian market (7.9% per year).

High Growth Revenue: CURA's revenue (28.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CURA's Return on Equity is forecast to be low in 3 years time (12.8%).


Next Steps

Past Performance

How has Curaleaf Holdings performed over the past 5 years?

-49.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CURA is currently unprofitable.

Growing Profit Margin: CURA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CURA is unprofitable, and losses have increased over the past 5 years at a rate of 49.5% per year.

Accelerating Growth: Unable to compare CURA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CURA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).


Return on Equity

High ROE: CURA has a negative Return on Equity (-3.85%), as it is currently unprofitable.


Next Steps

Financial Health

How is Curaleaf Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: CURA's short term assets ($376.9M) exceed its short term liabilities ($177.2M).

Long Term Liabilities: CURA's short term assets ($376.9M) do not cover its long term liabilities ($796.4M).


Debt to Equity History and Analysis

Debt Level: CURA's debt to equity ratio (20.2%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CURA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CURA has sufficient cash runway for 9 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: Insufficient data to determine if CURA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Curaleaf Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CURA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CURA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CURA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CURA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CURA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.9yrs

Average management tenure


CEO

Joe Bayern (57 yo)

no data

Tenure

Mr. Joseph Daniel Bayern, also known as Joe, has been Chief Executive Officer of Curaleaf Holdings, Inc. since January 1, 2021. He served as the President at Curaleaf Holdings, Inc. since joining December ...


Leadership Team

NamePositionTenureCompensationOwnership
Boris Jordan
Executive Chairmanno dataUS$750.00k19.08%
$ 2.6b
Joseph Lusardi
Executive Vice-Chairmanno dataUS$1.01m0.56%
$ 74.9m
Neil Davidson
COO & Treasurer0.92yrUS$538.50k0.034%
$ 4.5m
Joseph Bayern
Chief Executive Officerno datano data0.015%
$ 2.0m
Michael Carlotti
Chief Financial Officer0.92yrno datano data
Daniel Foley
Vice President of Finance & Investor Relationsno datano datano data
Peter Clateman
Chief Legal Officer1yrno data0.068%
$ 9.1m
James Shorris
Chief Compliance Officer0.83yrno data0.00015%
$ 20.1k
Tracy Brady
Vice President of Corporate Communications1.08yrsno datano data
Jason White
Chief Marketing Officer0.92yrno datano data
Carolyn Fedigan
Senior Vice President of Human Resourcesno datano data0.0082%
$ 1.1m
Ed Kelenchuk
Senior Vice President of Business Developmentno datano data0.029%
$ 3.9m

0.9yrs

Average Tenure

50.5yo

Average Age

Experienced Management: CURA's management team is not considered experienced ( 0.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Boris Jordan
Executive Chairmanno dataUS$750.00k19.08%
$ 2.6b
Joseph Lusardi
Executive Vice-Chairmanno dataUS$1.01m0.56%
$ 74.9m
Mitchell Kahn
Independent Director0.50yrno data0.74%
$ 98.8m
Peter Derby
Independent Director2.25yrsUS$100.00k0.067%
$ 9.0m
Karl Johansson
Independent Director2.25yrsUS$100.00k0.0061%
$ 816.2k
Steven Patierno
Chairman of the Medical Advisory Boardno dataUS$50.00kno data
David Casarett
Member of the Medical Advisory Boardno datano datano data
Robert Schnoll
Member of the Medical Advisory Boardno datano datano data
Jaswinder Grover
Independent Director0.92yrno data0.80%
$ 107.2m

1.6yrs

Average Tenure

59yo

Average Age

Experienced Board: CURA's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CURA insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 41.8%.


Top Shareholders

Company Information

Curaleaf Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Curaleaf Holdings, Inc.
  • Ticker: CURA
  • Exchange: CNSX
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$13.425b
  • Shares outstanding: 683.20m
  • Website: https://www.curaleaf.com

Number of Employees


Location

  • Curaleaf Holdings, Inc.
  • 301 Edgewater Place
  • Suite 405
  • Wakefield
  • Massachusetts
  • 1880
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CURACNSX (Canadian National Stock Exchange)YesSubordinated Voting SharesCACADOct 2018
CURL.FOTCPK (Pink Sheets LLC)YesSubordinated Voting SharesUSUSDOct 2018

Biography

Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Ope...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/20 00:38
End of Day Share Price2021/01/19 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.